Float Short %

13.37

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.05

EPS Last/This Y

0.05

EPS This/Next Y

0.48

Price

11.8

Target Price

23.12

Analyst Recom

1.22

Performance Q

37.46

Upside

-542.7%

Beta

-1.27

Ticker: DAWN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	DAWN	11.95	0.38	0.17	51905
2026-01-26	DAWN	12.03	0.38	0.02	53478
2026-01-27	DAWN	12.34	0.37	0.04	53939
2026-01-28	DAWN	11.77	0.37	0.05	54208
2026-01-29	DAWN	11.15	0.37	0.75	54541
2026-01-30	DAWN	11.16	0.37	0.09	55224
2026-02-02	DAWN	11.52	0.37	0.76	55410
2026-02-03	DAWN	11.18	0.38	1.65	56699
2026-02-04	DAWN	10.75	0.38	0.49	56872
2026-02-05	DAWN	10.49	0.38	0.00	58615
2026-02-06	DAWN	11.41	0.42	0.02	54494
2026-02-09	DAWN	11.73	0.42	0.06	54553
2026-02-10	DAWN	11.43	0.42	0.01	54465
2026-02-11	DAWN	11.23	0.42	0.02	54515
2026-02-12	DAWN	11	0.42	0.00	54576
2026-02-13	DAWN	11.36	0.42	0.14	54664
2026-02-17	DAWN	11.89	0.42	0.02	54745
2026-02-18	DAWN	11.56	0.41	0.04	55151
2026-02-19	DAWN	12.09	0.41	0.65	55357
2026-02-20	DAWN	11.81	0.41	1.04	55552
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	DAWN	11.95	72.6	-	-0.97
2026-01-26	DAWN	12.03	72.6	-	-0.97
2026-01-27	DAWN	12.34	72.6	-	-0.97
2026-01-28	DAWN	11.78	72.6	-	-0.97
2026-01-29	DAWN	11.15	72.6	-	-0.97
2026-01-30	DAWN	11.15	72.6	-	-0.97
2026-02-02	DAWN	11.51	72.6	-	-0.97
2026-02-03	DAWN	11.17	72.6	-	-0.97
2026-02-04	DAWN	10.74	72.6	-	-0.97
2026-02-05	DAWN	10.49	72.6	-	-0.97
2026-02-06	DAWN	11.40	72.6	-	-0.97
2026-02-09	DAWN	11.73	75.6	-	-0.97
2026-02-10	DAWN	11.41	75.6	-	-0.97
2026-02-11	DAWN	11.23	75.6	-	-0.97
2026-02-12	DAWN	11.01	75.6	-	-0.97
2026-02-13	DAWN	11.37	75.6	-	-0.97
2026-02-17	DAWN	11.90	75.7	-	-0.97
2026-02-18	DAWN	11.57	75.7	-	-0.97
2026-02-19	DAWN	12.06	75.7	-	-0.97
2026-02-20	DAWN	11.80	76.0	-	-0.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	DAWN	-0.19	-0.01	14.74
2026-01-26	DAWN	-0.19	0.23	14.74
2026-01-27	DAWN	-0.19	0.23	14.74
2026-01-28	DAWN	-0.19	0.23	15.00
2026-01-29	DAWN	-0.19	0.23	15.00
2026-01-30	DAWN	-0.19	0.23	15.00
2026-02-02	DAWN	-0.19	0.19	15.00
2026-02-03	DAWN	-0.19	0.19	15.00
2026-02-04	DAWN	-0.19	0.19	15.00
2026-02-05	DAWN	-0.19	0.19	15.00
2026-02-06	DAWN	-0.19	0.19	15.00
2026-02-09	DAWN	-0.19	1.23	15.00
2026-02-10	DAWN	-0.19	1.23	15.00
2026-02-11	DAWN	-0.19	1.23	13.49
2026-02-12	DAWN	-0.19	1.23	13.49
2026-02-13	DAWN	-0.19	1.23	13.49
2026-02-17	DAWN	-0.19	2.07	13.33
2026-02-18	DAWN	-0.32	2.07	13.33
2026-02-19	DAWN	-0.32	2.07	13.37
2026-02-20	DAWN	-0.22	2.07	13.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.19

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

-0.22

Institutional Transactions

2.07

Beta

-1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

58.9

Max Drawdown 5-Year %

Target Price

23.12

P/E

Forward P/E

PEG

P/S

9.32

P/B

2.68

P/Free Cash Flow

EPS

-1.49

Average EPS Est. Cur. Y

-0.97

EPS Next Y. (Est.)

-0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-113.53

Relative Volume

0.53

Return on Equity vs Sector %

-62.7

Return on Equity vs Industry %

-45.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

Day One Biopharmaceuticals, Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 184

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

stock quote shares DAWN – Day One Biopharmaceuticals, Inc. Stock Price stock today

news today DAWN – Day One Biopharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DAWN – Day One Biopharmaceuticals, Inc. yahoo finance google finance

stock history DAWN – Day One Biopharmaceuticals, Inc. invest stock market

stock prices DAWN premarket after hours

ticker DAWN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: DAWN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y